Adimmune

Adimmune Corporation, established in 1965, is a prominent player in the manufacturing sector, specializing in vaccine production. The company holds the distinction of being the sole influenza vaccine manufacturer in Asia with both EU GMP and US FDA certifications. Furthermore, Adimmune is recognized as the only PIC/S GMP manufacturer of human vaccines within Taiwan, underscoring its commitment to stringent quality standards and global regulatory compliance. Its operational base is situated in Taichung City, Taiwan, contributing to the Asia-Pacific region's pharmaceutical landscape.

The company's product portfolio is diverse, featuring Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), Tetanus toxoid, and purified Tuberculin. Adimmune operates with a workforce ranging from 500 - 1,000 employees, dedicated to research, development, and manufacturing excellence. This team's expertise is crucial in maintaining the company's advanced production capabilities and ensuring the efficacy and safety of its pharmaceutical offerings. Meet Adimmune's team to understand the leadership driving these operations.

With a reported revenue of $78.2M, Adimmune demonstrates significant market presence within the chemicals, petrochemicals, glass & gases, and manufacturing industries. Its ticker symbol, TWSE: 4142, signifies its public trading status. The company's strategic focus on critical human vaccines and toxoids positions it as a key contributor to public health initiatives, both domestically and internationally, leveraging its advanced certifications and manufacturing prowess.